肾癌病因中肥胖相关风险因素的系统评估:纵向风险与孟德尔随机化分析
研究采用UK Biobank队列(472,337人,1,382例肾癌)和NSHDS队列,结合两样本孟德尔随机化(27,213例病例/486,846例对照),系统评估肥胖相关风险因素在肾癌病因中的中介作用。发现空腹胰岛素、甘油三酯、舒张压与肾癌风险正相关,性激素结合球蛋白和高密度脂蛋白胆固醇与风险负相关,提示这些因素介导肥胖与肾癌的关联。
要点
- 空腹胰岛素、甘油三酯、舒张压升高与肾癌风险正相关
- 性激素结合球蛋白和高密度脂蛋白胆固醇升高与肾癌风险负相关
- 这些肥胖相关因素可能介导肥胖与肾癌的关联
核心结论
- 空腹胰岛素、高密度脂蛋白胆固醇、舒张压、甘油三酯和性激素结合球蛋白在介导身体肥胖与肾癌风险关系中发挥作用。
研究设计与样本
- 研究采用两种互补方法:基于UK Biobank队列(472,337名参与者,随访5,586,414人年期间诊断1,382例新发肾癌)和NSHDS队列(空腹胰岛素204对病例对照)的直接风险因素评估,以及基于肾癌GWAS(27,213例病例,486,846例对照)的两样本孟德尔随机化分析。
- 队列分析使用Cox比例风险回归模型,调整年龄、性别、招募中心、教育、吸烟和饮酒状态;孟德尔随机化采用逆方差加权法。
- 对在队列和MR分析中与肾癌风险方向一致的风险因素,使用乘积法进行中介分析。
主要发现
- 空腹胰岛素每增加一个标准差:MR OR=2.24(95%CI 1.19-4.22,p=0.01),队列HR=1.43(95%CI 1.02-2.00,p=0.04)。
- 甘油三酯每增加一个标准差:MR OR=1.11(95%CI 1.05-1.17,p<0.001),队列HR=1.23(95%CI 1.11-1.38,p<0.001)。
- 舒张压每增加一个标准差:MR OR=1.14(95%CI 1.04-1.26,p<0.001),队列HR=1.11(95%CI 1.05-1.17,p<0.001)。
- 性激素结合球蛋白每增加一个标准差:MR OR=0.80(95%CI 0.70-0.90,p<0.001),队列HR=0.67(95%CI 0.58-0.76,p<0.001)。
- 高密度脂蛋白胆固醇每增加一个标准差:MR OR=0.93(95%CI 0.88-0.98,p<0.001),队列HR=0.72(95%CI 0.66-0.77,p<0.001)。
临床怎么用
- 在肾癌风险评估中,可关注空腹胰岛素、血脂、血压和性激素结合球蛋白等肥胖相关代谢指标。
- 针对这些中介因素的干预可能有助于降低肥胖相关肾癌风险,但需进一步研究验证。
局限性
- 研究对某些风险因素的统计功效有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Excess body adiposity is an established cause of renal cancer, but underlying molecular pathways mediating this relationship remain unclear. This study aimed to systematically evaluate a panel of obesity-related risk factors as potential mediators in renal cancer etiology. METHODS AND FINDINGS: We used two complementary approaches to evaluate obesity-related risk factors in renal cancer etiology: (i) direct risk factor assessment in longitudinal cohorts and (ii) genetically proxied risk factors through two-sample Mendelian randomization (MR). Direct risk-factor association-analyses (i.e., cohort analyses) were based on the UK Biobank cohort study (472,337 cohort participants, including 1,382 incident renal cancer cases diagnosed during 5,586,414 person years of follow-up) and the Northern Sweden Health and Disease Study (NSHDS) for fasting insulin (204 pairs of cases and controls, ongoing recruitment and follow-up since 1985). We used Cox proportional hazards regression models to evaluate the association between risk factors and renal cancer risk with adjustment for age, sex, center of recruitment, education, smoking and alcohol drinking status. Two-sample MR analyses were based on a genome-wide association study (GWAS) of renal cancer (27,213 cases, 486,846 controls). We used the inverse-variance weighted (IVW) approach to estimate the association between risk factors and renal cancer risk. Mediation analyses were performed for traits displaying directionally consistent associations with renal cancer risk in both the cohort and MR analyses using the product method. We found consistent positive associations with renal cancer risk for fasting insulin (odds ratio per standard deviation increment [ORMR]: 2.24, 95% confidence interval [95% CI]: 1.19, 4.22; p = 0.01; hazard ratio per standard deviation increment [HRcohort]: 1.43, 95% CI: 1.02, 2.00; p = 0.04), triglycerides (ORMR: 1.11, 95% CI: 1.05, 1.17; p < 0.001, HRcohort: 1.23, 95% CI: 1.11, 1.38; p < 0.001), diastolic blood pressure (DBP) (ORMR: 1.14, 95% CI: 1.04, 1.26; p < 0.001, HRcohort: 1.11, 95% CI: 1.05, 1.17; p < 0.001) and consistent inverse associations with renal cancer risk for sex-hormone binding globulin (SHBG) (ORMR: 0.80, 95% CI: 0.70, 0.90; p < 0.001, HRcohort: 0.67, 95% CI: 0.58, 0.76; p < 0.001) and high-density lipoprotein (HDL) cholesterol (ORMR: 0.93, 95% CI: 0.88, 0.98; p < 0.001, HRcohort: 0.72, 95% CI: 0.66, 0.77; p < 0.001). The main limitation of this study was that we had limited statistical power to evaluate some risk factors. CONCLUSIONS: Our study highlights roles for fasting insulin, HDL cholesterol, DBP, triglycerides and SHBG in mediating the relationship between body adiposity and renal cancer risk.
引用
- Alcala K, Mariosa D, Jacobson S, et al. Systematic assessment of obesity-related risk factors in renal cancer etiology: A longitudinal risk and Mendelian randomization analysis. PLoS Med. 2026. PMID: 41666231. doi:10.1371/journal.pmed.1004906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。